Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe site revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check18 days agoChange DetectedRevision: v3.4.3 was added, replacing Revision: v3.4.2. This appears to be a minor UI/versioning update and does not affect the study information.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check40 days agoChange DetectedRevision: v3.4.2 was applied, replacing the previous v3.4.1. This update seems to be a metadata/version change with no visible impact on study details or page content.SummaryDifference0.0%

- Check47 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed, indicating a minor internal software update with no changes to page content or trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check54 days agoChange DetectedAdds a glossary toggle and new update timestamp labels (Last Update Submitted that Met QC Criteria and Last Update Posted) to the study details page, while removing the older QC label, the 'Last Update Posted (Estimated)' tag, the 'No FEAR Act data' wording, and the previous revision tag (v3.3.4).SummaryDifference0.1%

- Check68 days agoChange DetectedThe page shows a minor site revision from v3.3.3 to v3.3.4 with no changes to study content or page behavior. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.